In TNBC, PD-L1 expression in TAMs is associated with a better OS [144] and a higher pCR rate to neoadjuvant ICI [83,145]; further, in HR+/HER2− BC patients, a higher intratumoral density of CD163+ M2-TAMs is enriched in responders that have NACT combined with ICI and hormone therapy (HT) [23]. This evidence concerns the gene CD274 and breast cancer.